GlassScriptPhysician profile
Anil Chopra
NPI 1205836236
$9,437.83
in general payments reported to CMS, 2019-2025
42 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $1,137 · 2021: $2,149 · 2022: $1,469 · 2023: $1,380 · 2024: $1,196 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.55 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.45 | 2020-2024 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,395.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $802.11 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $588.70 | 2019-2025 | |
| Allergan, INC. | $522.82 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $484.66 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $358.07 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $346.81 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.16 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $340.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $302.04 | 2019-2022 | |
| Astellas Pharma US INC | $269.69 | 2021-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.57 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $224.42 | 2019-2024 | Rexulti |
| Abbott Laboratories | $168.15 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.